Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven P Angus

Showing results (41-50 of 60) with videos related to

Pageof 6
Sort By:
Scientific Reports|August 24, 2021
High-content image-based analysis and proteomic profiling identifies Tau phosphorylation inhibitors in a human iPSC-derived glutamatergic neuronal model of tauopathyChialin Cheng, Surya A Reis, Emily T Adams, et al.
Human Molecular Genetics|October 19, 2018
A proteasome-resistant fragment of NIK mediates oncogenic NF-κB signaling in schwannomasJeffrey R Gehlhausen, Eric Hawley, Benjamin Mark Wahle, et al.
Cell Reports|April 14, 2015
Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family BromodomainsTimothy J Stuhlmiller, Samantha M Miller, Jon S Zawistowski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 5, 2023
Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform NeurofibromaAlyssa C Flint, Dana K Mitchell, Steven P Angus, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 1, 2024
Correction: Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform NeurofibromaAlyssa C Flint, Dana K Mitchell, Steven P Angus, et al.
Cancer Discovery|January 22, 2017
Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacologic Targeting of the P-TEFb ComplexJon S Zawistowski, Samantha M Bevill, Daniel R Goulet, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 10, 2025
DLK1 Distinguishes Subsets of NF1-Associated Malignant Peripheral Nerve Sheath Tumors with Divergent Molecular SignaturesDana K Mitchell, Kylee Brewster, Stavriani C Makri, et al.
HGG Advances|April 30, 2026
Genetic activation of ERK2 recapitulates core neurodevelopmental features of Rasopathy syndromes in miceKassidy E Grover, Zoe R Cappel, Avery Volz, et al.
Neuro-Oncology|April 6, 2017
Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastomaRobert S McNeill, Demitra A Canoutas, Timothy J Stuhlmiller, et al.
Acta Neuropathologica Communications|June 28, 2025
Identifying and exploiting combinatorial synthetic lethality by characterizing adaptive kinome rewiring of EGFRvIII-driven glioblastomaBenjamin Lin, Abigail K Shelton, Erin Smithberger, et al.
Pageof 6

Showing results (41-50 of 60) with videos related to

Sort By:
Pageof 6
Scientific Reports|August 24, 2021
High-content image-based analysis and proteomic profiling identifies Tau phosphorylation inhibitors in a human iPSC-derived glutamatergic neuronal model of tauopathyChialin Cheng, Surya A Reis, Emily T Adams, et al.
Human Molecular Genetics|October 19, 2018
A proteasome-resistant fragment of NIK mediates oncogenic NF-κB signaling in schwannomasJeffrey R Gehlhausen, Eric Hawley, Benjamin Mark Wahle, et al.
Cell Reports|April 14, 2015
Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family BromodomainsTimothy J Stuhlmiller, Samantha M Miller, Jon S Zawistowski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 5, 2023
Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform NeurofibromaAlyssa C Flint, Dana K Mitchell, Steven P Angus, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 1, 2024
Correction: Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform NeurofibromaAlyssa C Flint, Dana K Mitchell, Steven P Angus, et al.
Cancer Discovery|January 22, 2017
Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacologic Targeting of the P-TEFb ComplexJon S Zawistowski, Samantha M Bevill, Daniel R Goulet, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 10, 2025
DLK1 Distinguishes Subsets of NF1-Associated Malignant Peripheral Nerve Sheath Tumors with Divergent Molecular SignaturesDana K Mitchell, Kylee Brewster, Stavriani C Makri, et al.
HGG Advances|April 30, 2026
Genetic activation of ERK2 recapitulates core neurodevelopmental features of Rasopathy syndromes in miceKassidy E Grover, Zoe R Cappel, Avery Volz, et al.
Neuro-Oncology|April 6, 2017
Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastomaRobert S McNeill, Demitra A Canoutas, Timothy J Stuhlmiller, et al.
Acta Neuropathologica Communications|June 28, 2025
Identifying and exploiting combinatorial synthetic lethality by characterizing adaptive kinome rewiring of EGFRvIII-driven glioblastomaBenjamin Lin, Abigail K Shelton, Erin Smithberger, et al.
Pageof 6